This is a proof (draft) Hansard, not the final version.
The Parliament has not yet published the final text for this day, so the wording, who said what and the results of divisions may change.
Senate debates Bills
Therapeutic Goods Amendment (Medicines Shortages and Other Measures) Bill 2026, Therapeutic Goods (Charges) Amendment Bill 2026; Second Reading
Jenny McAllister NSW, Australian Labor Party, Minister for the National Disability Insurance Scheme
7:37 pm
Many improvements have been made to arrangements to deal with medicines shortages and discontinuance reporting since the introduction of these arrangements in 2019, but supply disruptions do continue to impact the health and wellbeing of people in Australia and the health practitioners and systems that support them. The bill before the chamber, the Therapeutic Goods Amendment (Medicines Shortages and Other Measures) Bill, strengthens key aspects of the mandatory medicines shortage and discontinuation reporting scheme under the Therapeutic Goods Act, principally by requiring sponsors to notify the secretary of any decision to permanently discontinue the supply of reportable medicines in Australia at least 12 months in advance; requiring sponsors who give such notice to update the secretary if there is a change in that approach, including if the supply is no longer proposed to be discontinued or if the discontinuation is to occur at a different time to that notified; and enabling the secretary to require all sponsors of approved medicines to provide information about the availability and any shortage or discontinuation of their products in Australia.
These amendments are consistent with this government's unwavering commitment to public health, and will mitigate the public health risks associated with medicines shortages and discontinuations, by supporting a strong and effective mandatory reporting scheme under the Therapeutic Goods Act. Together with the associated amendments in the Therapeutic Goods (Charges) Amendment Bill 2026, the bill will implement measures to reduce costs and regulatory burden for sponsors who have multiple biologicals in the Australian Register of Therapeutic Goods. These amendments are consistent with this government's commitment to reducing regulatory burden. The other minor amendments in the bill will support the consistent and effective operation of the Therapeutic Goods Act and the therapeutic goods regulatory framework. I thank members for their contribution to the debate on these bills.
Question agreed to.
Bills read a second time.
(Quorum formed)
No comments